Euangelion original data figure
Created: 2026-10-20
Original SVG authored by Euangelion from the October 19, 2026 FDA accelerated-approval summary for dostarlimab-gxly (AZUR-1 trial, NCT05723562, N=154). Zero-based 0–154 patient partition. Accelerated approval applies only to the ~3% of locally advanced rectal cancers that are dMMR/MSI-H.
Source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer
Rights: Original composition licensed CC BY 4.0. No third-party image or logo used.